given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. paroxetinemethylphenidate transdermal will increase the level or effect of paroxetine by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. perampanelmethylphenidate transdermal will increase the level or effect of perampanel by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. perindoprilmethylphenidate transdermal decreases effects of perindopril by anti-hypertensive channel blocking. Use Caution/Monitor.phenobarbitalmethylphenidate transdermal will increase the level or effect of phenobarbital by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. phenytoinmethylphenidate transdermal will increase the level or effect of phenytoin by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. pregabalinmethylphenidate transdermal will increase the level or effect of pregabalin by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. primidonemethylphenidate transdermal will increase the level or effect of primidone by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. propranololmethylphenidate transdermal decreases effects of propranolol by anti-hypertensive channel blocking. Use Caution/Monitor.protriptylinemethylphenidate transdermal will increase the level or effect of protriptyline by decreasing elimination. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. quinaprilmethylphenidate transdermal decreases effects of quinapril by anti-hypertensive channel blocking. Use Caution/Monitor.ramiprilmethylphenidate transdermal decreases effects of ramipril by anti-hypertensive channel blocking. Use Caution/Monitor.risperidonemethylphenidate transdermal will increase the level or effect of risperidone by unspecified interaction mechanism. Use Caution/Monitor. When coadministered with methylphenidate, changes in dosage of either or both medications, may increase the risk of extrapyramidal symptoms (EPS). Monitor for signs of EPS.rufinamidemethylphenidate transdermal will increase the level or effect of rufinamide by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. sacubitril/valsartanmethylphenidate transdermal decreases effects of sacubitril/valsartan by anti-hypertensive channel blocking. Use Caution/Monitor.sertralinemethylphenidate transdermal will increase the level or effect of sertraline by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. sotalolmethylphenidate transdermal decreases effects of sotalol by anti-hypertensive channel blocking. Use Caution/Monitor.spironolactonemethylphenidate transdermal decreases effects of spironolactone by anti-hypertensive channel blocking. Use Caution/Monitor.stiripentolmethylphenidate transdermal will increase the level or effect of stiripentol by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. telmisartanmethylphenidate transdermal decreases effects of telmisartan by anti-hypertensive channel blocking. Use Caution/Monitor.terlipressinmethylphenidate transdermal and terlipressin both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.tiagabinemethylphenidate transdermal will increase the level or effect of tiagabine by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. tolvaptanmethylphenidate transdermal and tolvaptan both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.topiramatemethylphenidate transdermal will increase the level or effect of topiramate by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. trandolaprilmethylphenidate transdermal decreases effects of trandolapril by anti-hypertensive channel blocking. Use Caution/Monitor.triamterenemethylphenidate transdermal decreases effects of triamterene by anti-hypertensive channel blocking. Use Caution/Monitor.trimipraminemethylphenidate transdermal will increase the level or effect of trimipramine by decreasing elimination. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. valproic acidmethylphenidate transdermal will increase the level or effect of valproic acid by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. valsartanmethylphenidate transdermal decreases effects of valsartan by anti-hypertensive channel blocking. Use Caution/Monitor.vasopressinmethylphenidate transdermal and vasopressin both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.vigabatrinmethylphenidate transdermal will increase the level or effect of vigabatrin by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. warfarinmethylphenidate transdermal will increase the level or effect of warfarin by decreasing metabolism. Modify Therapy/Monitor Closely. Decreasing the dose of these drugs may be required when given coadministered with methylphenidate. Consider monitoring plasma drug concentrations (or INR with coumadin), when initiating or discontinuing methylphenidate. zonisamidemethylphenidate transdermal will increase the level or effect of zonisamide by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. Minor (0)acebutololMonitor Closely (1)methylphenidate transdermal decreases effects of acebutolol by anti-hypertensive channel blocking. Use Caution/Monitor.acetazolamideMonitor Closely (1)methylphenidate transdermal will increase the level or effect of acetazolamide by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. amilorideMonitor Closely (1)methylphenidate transdermal decreases effects of amiloride by anti-hypertensive channel blocking. Use Caution/Monitor.amitriptylineMonitor Closely (1)methylphenidate transdermal will increase the level or effect of amitriptyline by decreasing elimination. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. amoxapineMonitor Closely (1)methylphenidate transdermal will increase the level or effect of amoxapine by decreasing elimination. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. azilsartanMonitor Closely (1)methylphenidate transdermal decreases effects of azilsartan by anti-hypertensive channel blocking. Use Caution/Monitor.benazeprilMonitor Closely (1)methylphenidate transdermal decreases effects of benazepril by anti-hypertensive channel blocking. Use Caution/Monitor.candesartanMonitor Closely (1)methylphenidate transdermal decreases effects of candesartan by anti-hypertensive channel blocking. Use Caution/Monitor.cannabidiolMonitor Closely (1)methylphenidate transdermal will increase the level or effect of cannabidiol by anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. captoprilMonitor Closely (1)methylphenidate transdermal decreases effects of captopril by anti-hypertensive channel blocking. Use Caution/Monitor.carbamazepineMonitor Closely (1)methylphenidate transdermal will increase the level or effect of carbamazepine by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. cenobamateMonitor Closely (1)methylphenidate transdermal will increase the level or effect of cenobamate by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. chlorothiazideMonitor Closely (1)methylphenidate transdermal decreases effects of chlorothiazide by anti-hypertensive channel blocking. Use Caution/Monitor.chlorthalidoneMonitor Closely (1)methylphenidate transdermal decreases effects of chlorthalidone by anti-hypertensive channel blocking. Use Caution/Monitor.citalopramMonitor Closely (1)methylphenidate transdermal will increase the level or effect of citalopram by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. clobazamMonitor Closely (1)methylphenidate transdermal will increase the level or effect of clobazam by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. clomipramineMonitor Closely (1)methylphenidate transdermal will increase the level or effect of clomipramine by decreasing elimination. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. clonazepamMonitor Closely (1)methylphenidate transdermal will increase the level or effect of clonazepam by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. clorazepateMonitor Closely (1)methylphenidate transdermal will increase the level or effect of clorazepate by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. conivaptanMonitor Closely (1)methylphenidate transdermal and conivaptan both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.desipramineMonitor Closely (1)methylphenidate transdermal will increase the level or effect of desipramine by decreasing elimination. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. desmopressinMonitor Closely (1)methylphenidate transdermal and desmopressin both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.diazepamMonitor Closely (1)methylphenidate transdermal will increase the level or effect of diazepam by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. diazepam buccalMonitor Closely (1)methylphenidate transdermal will increase the level or effect of diazepam buccal by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. diazepam intranasalMonitor Closely (1)methylphenidate transdermal will increase the level or effect of diazepam intranasal by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. divalproex sodiumMonitor Closely (1)methylphenidate transdermal will increase the level or effect of divalproex sodium by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. doxepinMonitor Closely (1)methylphenidate transdermal will increase the level or effect of doxepin by decreasing elimination. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. enalaprilMonitor Closely (1)methylphenidate transdermal decreases effects of enalapril by anti-hypertensive channel blocking. Use Caution/Monitor.eprosartanMonitor Closely (1)methylphenidate transdermal decreases effects of eprosartan by anti-hypertensive channel blocking. Use Caution/Monitor.escitalopramMonitor Closely (1)methylphenidate transdermal will increase the level or effect of escitalopram by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. eslicarbazepine acetateMonitor Closely (1)methylphenidate transdermal will increase the level or effect of eslicarbazepine acetate by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. esmololMonitor Closely (1)methylphenidate transdermal decreases effects of esmolol by anti-hypertensive channel blocking. Use Caution/Monitor.ethosuximideMonitor Closely (1)methylphenidate transdermal will increase the level or effect of ethosuximide by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. ethotoinMonitor Closely (1)methylphenidate transdermal will increase the level or effect of ethotoin by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. ezogabineMonitor Closely (1)methylphenidate transdermal will increase the level or effect of ezogabine by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. felbamateMonitor Closely (1)methylphenidate transdermal will increase the level or effect of felbamate by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. fenfluramineMonitor Closely (1)methylphenidate transdermal will increase the level or effect of fenfluramine by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. fluoxetineMonitor Closely (1)methylphenidate transdermal will increase the level or effect of fluoxetine by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. fluvoxamineMonitor Closely (1)methylphenidate transdermal will increase the level or effect of fluvoxamine by decreasing metabolism. Modify Therapy/Monitor Closely. Consider